Most Read Articles
Roshini Claire Anthony, one year ago
Earlier age of menarche is significantly linked to a higher risk of gestational diabetes mellitus (GDM) independent of other risk factors, according to a recent study.
one year ago
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Elvira Manzano, one year ago
Hyperbaric oxygen therapy improves long-term survival in patients with chronic diabetic foot ulcers, according to 6-year follow-up data from the HODFU* study.
one year ago
This newsletter reports recent updates on diabetes management from the 18th ASEAN Federation of Endocrine Societies (AFES) Congress held in Kuala Lumpur, Malaysia, with a special highlight on the use of biosimilar insulins in managing diabetes.

Surgery, medical programme improve physical behaviour, fitness in T2D patients

5 months ago

In patients with type 2 diabetes (T2D), both Roux-en-Y gastric bypass and the medical programme result in therapeutic lifestyle changes and improved objective and self-reported physical fitness, according to a recent study.

Heart rate, oxygen saturation and perceived impact of weight on health had also improved after surgery, and this could have been caused by greater weight loss.

Researchers assessed the physical behaviour and fitness in participants of the Surgery or Lifestyle With Intensive Medical Management in the Treatment of Type 2 Diabetes (SLIMM-T2D) study, with the purpose of comparing the effects of Roux-en-Y gastric bypass with a multidisciplinary, group-based medical diabetes and weight management programme.

SLIMM-T2D is a randomized, parallel-group trial conducted at a US academic hospital and diabetes clinic with 18- to 24-month follow-up. A total of 38 T2D patients with haemoglobin A1c ≥6.5 percent and body mass index (BMI) 30 to 42 kg/m2 were randomly assigned to either Roux-en-Y gastric bypass or the medical programme.

Researchers conducted a 6-minute walk test to evaluate fitness, self-reported physical activity, standardized physical surveys and cardiometabolic risk assessment at baseline and after intervention.

Improvement in the 6-minute walk test distance was seen in both groups, with greater improvements in oxygen saturation and reduced heart rate after surgery.

At 18 to 24 months after interventions, self-reported physical activity similarly improved, while exercise increased gradually after surgery. However, early substantial increases in the medical group were not fully sustained.

After surgery, self-reported total and physical health were similar by Short Form-36 but improved more in the Impact of Weight on Quality of Life survey. Furthermore, greater improvement was found in cardiovascular risk scores, HbA1c and BMI after surgery.

Further research is warranted to better understand the clinical importance of these improvement with greater weight loss, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, one year ago
Earlier age of menarche is significantly linked to a higher risk of gestational diabetes mellitus (GDM) independent of other risk factors, according to a recent study.
one year ago
Good glycaemic control and minimizing CV risk factors are the cornerstones of T2D management. Empagliflozin, a SGLT2 inhibitor, has a unique mechanism of action that not only lowers plasma glucose but also other CV risk factors. The EMPA-REG OUTCOME® trial explored the CV benefits of this drug, and a panel of eminent speakers gathered recently to present the implications of this study and empagliflozin on clinical practice.
Elvira Manzano, one year ago
Hyperbaric oxygen therapy improves long-term survival in patients with chronic diabetic foot ulcers, according to 6-year follow-up data from the HODFU* study.
one year ago
This newsletter reports recent updates on diabetes management from the 18th ASEAN Federation of Endocrine Societies (AFES) Congress held in Kuala Lumpur, Malaysia, with a special highlight on the use of biosimilar insulins in managing diabetes.